Bamco Inc. NY Trims Position in argenx SE (NASDAQ:ARGX)

Bamco Inc. NY trimmed its position in argenx SE (NASDAQ:ARGX) by 3.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,178 shares of the company’s stock after selling 8,126 shares during the quarter. Bamco Inc. NY owned approximately 0.40% of argenx worth $148,939,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Bayesian Capital Management LP lifted its stake in argenx by 38.0% in the 4th quarter. Bayesian Capital Management LP now owns 621 shares of the company’s stock worth $382,000 after purchasing an additional 171 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of argenx by 138.4% in the fourth quarter. BNP Paribas Financial Markets now owns 10,232 shares of the company’s stock worth $6,293,000 after purchasing an additional 5,940 shares during the period. Ameriprise Financial Inc. raised its position in shares of argenx by 10.0% in the fourth quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company’s stock worth $4,313,000 after buying an additional 639 shares in the last quarter. Acuta Capital Partners LLC boosted its stake in argenx by 17.1% during the fourth quarter. Acuta Capital Partners LLC now owns 6,910 shares of the company’s stock valued at $4,250,000 after buying an additional 1,010 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in argenx during the fourth quarter worth about $17,158,000. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Up 1.5 %

NASDAQ:ARGX opened at $649.67 on Friday. The firm has a market capitalization of $39.67 billion, a P/E ratio of -738.26 and a beta of 0.57. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The company has a fifty day moving average of $598.32 and a 200 day moving average of $611.86.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. As a group, analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ARGX shares. Citigroup lifted their price target on argenx from $681.00 to $796.00 and gave the company a “buy” rating in a research report on Thursday, April 17th. Truist Financial reiterated a “buy” rating and set a $700.00 target price (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. HC Wainwright reaffirmed a “buy” rating and set a $720.00 price objective on shares of argenx in a report on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research note on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus target price of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.